



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/533,104

04/28/2005

Yong Kwee

053466-0401

5920

22428 7590 12/04/2008  
FOLEY AND LARDNER LLP  
SUITE 500  
3000 K STREET NW  
WASHINGTON, DC 20007

EXAMINER

SANG, HONG

ART UNIT

PAPER NUMBER

1643

MAIL DATE

DELIVERY MODE

12/04/2008

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address : COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10533104	4/28/2005	KWEE ET AL.	053466-0401

FOLEY AND LARDNER LLP  
SUITE 500  
3000 K STREET NW  
WASHINGTON, DC 20007

**EXAMINER**

HONG SANG

**ART UNIT****PAPER**

1643

20081201

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner for Patents**

The reply filed 10/23/2008 is not fully responsive to the communication mailed 4/24/2008 for the reasons set forth below.

In the reply filed on 10/23/2003, claims 1, 3, 12, and 23 have been amended. New claims 24-31 have been added. The pending claims (the amended claims 1, 3, 12 and 23 and new claims 24-31) are drawn to a method for treating cancer comprising administering to a patient an antigen-specific dendritic cell pulsed by an HM1.24 protein or HM1.24 peptide.

The pending claims are directed to inventions that are independent or distinct from the invention originally claimed, which is drawn to a product, i.e. a cancer vaccine comprising as an active ingredient an antibody specific dendritic cell pulsed by an HM1.24 protein or HM1.24 peptide. Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, the pending claims are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03. Even though Applicants did not receive a Restriction/Election Requirement by default formerly pending claims 1, 3, 12 and 24 were the elected group and any other invention not reading on this originally presented group is deemed a non-elected invention.

2. Since the above-mentioned reply appears to be bona fide, applicant is given a TIME PERIOD of ONE (1) MONTH or THIRTY (30) DAYS, from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME LIMIT MAY BE GRANTED UNDER 37 CFR 1.136(a).

3. Any inquiry concerning this communication should be directed to Examiner Hong Sang, Art Unit 1643, whose telephone number is (571)272-8145.

/Hong Sang/  
Examiner, Art Unit 1643  
12/1/08